SLAM
LEGN icon

Swiss Life Asset Management’s Legend Biotech LEGN Stock Holding History

Swiss Life Asset Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$274K Sell
9,483
-2,875
-23% -$77.5K ﹤0.01% 1326
2026
Q1 		$224K Buy
+12,358
New +$236K ﹤0.01% 1317
2025
Q4 		– Sell
-7,701
Closed -$251K – 1401
2025
Q3 		$251K Buy
+7,701
New +$284K ﹤0.01% 1002

Other funds holding LEGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $292M AUM 75.01% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
IAMH
IvyRock Asset Management (HK) Sheung Wan, Hong Kong $177M AUM 10.49% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Swiss Life Asset Management's LEGN Position: Q2 2026 in Review

Swiss Life Asset Management reduced its Legend Biotech (LEGN) stake by 23% in Q2 2026, selling an estimated $77.5K and leaving 9,483 shares worth $274K. The position accounts for ﹤0.01% of the portfolio, ranked #1326.

Swiss Life Asset Management first reported a position in LEGN in Q3 2025 and has held it in 3 quarters since. 112 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Swiss Life Asset Management held 9,483 shares of Legend Biotech worth $274K as of Q2 2026.
  • Swiss Life Asset Management sold 2,875 Legend Biotech shares in Q2 2026, an estimated $77.5K.
  • Legend Biotech made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1326 holding.
  • Swiss Life Asset Management first reported a position in Legend Biotech in Q3 2025 and has held it in 3 quarters since.
  • 112 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.